Ann: Chair and CEO AGM Presentation, page-4

Surprising to see the sell off after Prescient’s AGM. It came to no surprise that they are looking to wrap up PTX-200 and avoid unnecessary expenditure given the list of the approved medications since PTX-200 commenced. What impressed as a LT shareholder was the level of honesty and professionalism throughout. We have great assets, we know that. But what I want to know is where the money is being spent and targeted in the next 6-24 months. It’s important to see how astute they are with their reserves and the plans they have with our (shareholder) funds. Investors typically say you don’t invest in a company for their projects as much as you invest in a company for the board and directors. I’m confident with our board of directors and always impressed by Steven. No doubt we are In a rough patch at the moment, but so is the rest of the market. Looking forward to the presentation of PTX-100 next month followed by FDA meetings for approval Q1/Q2. Registrational trial is massive but a phase 2 study if not excepted for registrational trial is still monumental! Looking forward to 2024